CRISPR-based de-extinction and endangered species restoration
Colossal applies CRISPR and advanced reproductive biology to restore extinct and endangered species. The tech stack is heavily weighted toward bioinformatics (Benchling, SnapGene) and lab infrastructure, with no cloud data platforms or ML tooling visible—reflecting a bench-science operation rather than a software-first biotech. Active hiring skews research and healthcare, concentrated at senior and mid-level, with pain points centered on scaling embryo development protocols and veterinary infrastructure across non-model organisms.
Colossal is a genomics and genetic engineering company headquartered in Dallas, TX, focused on species de-extinction and ecosystem restoration using CRISPR technology. The company works across three operational areas: next-generation sequencing and analysis, stem cell and embryo engineering (particularly in marsupials and livestock), and veterinary clinical protocols for preventative medicine. The organization combines bench research, animal husbandry, and clinical development—evidenced by active work on embryo production, anesthesia protocol design, and scaling animal care programs. Current headcount sits in the 51–200 range with accelerating hiring velocity.
Colossal focuses on next-gen sequencing, stem cell platform development for non-model species (particularly marsupials), in vitro embryo production with edited genomes, and clinical SOP development for preventative medicine.
Benchling and SnapGene are the primary bioinformatics platforms in the stack, paired with Linux environments (Red Hat, Ubuntu, Debian) and Python for computational work.
Colossal is headquartered in Dallas, TX and currently hires across the United States, with active roles in research, healthcare, animal care, and operations.
Other companies in the same industry, closest in size